Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06666855

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.

Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.

The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

There will be a bridging cohort and extension follow-up phase

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Open Angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with primary open angle glaucoma or ocular hypertension in both eyes.
  • Corrected visual acuity ≥0.2 in both eyes.
  • Anterior chamber angle grade ≥2 (Shaffer scale) in both eyes.
  • Central corneal thickness ≥480 μm to ≤600 μm in both eyes.
  • At completion of the washout phase, IOP ≥22 mmHg in at least one eye and ≤34 mmHg in both eyes at all measurement time points.

Exclusion criteria

  • Consider visual field disorder at risk for progression during the study based on the current clinical examination result.
  • Severe visual field disorder (e.g., mean deviation lower than -12 dB, as assessed by Humphrey field analyzer).
  • Any corneal abnormality or other condition potentially interfering with reliable applanation tonometry.
  • History of iritis or uveitis.
  • Presence of any active external ocular disease, inflammation, or infection of the eye or eyelids.
  • History of macular oedema, retinal detachment, or diabetic retinopathy, or current retinal disease at risk for progression during the study.
  • History of refractive keratotomy.
  • History of invasive surgery for glaucoma (including laser therapy).
  • Anterior segment or intraocular surgery (other than glaucoma) within 90 days prior to start of washout phase.
  • History of severe eye injury.
  • History of allergy to agents that were to be used during the study (e.g., benzalkonium chloride, instillation anesthetics, fluorescein, latanoprost eye drops).
  • Intended use of prohibited concomitant medications or therapies during the study.
  • Required use of contact lenses from 1 week before treatment phase initiation and during the study.
  • Pseudophakic eye, aphakic eye.
  • Current participation in another clinical study, or participation and treatment with study medication within 90 days before the start of the washout phase.
  • Females who are pregnant, nursing, or potentially pregnant (e.g., positive pregnancy test), planning a pregnancy during the study, or unable to use appropriate contraception during the study.

Treatment and study plan

DE-117B Eye Drops

Drug

Investigational Product: 0.002% DE-117B Eye Drops

latanoprost

Drug

Active Control: 0.005% Latanoprost Eye Drops

Primary outcomes

  1. Intraocular Pressure (IOP) at Week 4

    Time frame: Week 4

    Change from Baseline in Mean Diurnal IOP at Week 4

Secondary outcomes

  1. Percent Change in Intraocular Pressure (IOP)

    Time frame: Week 4

    Percent Change from Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 4

  2. Change and Percent Change in Intraocular Pressure (IOP)

    Time frame: Post baseline Visits except Week 4

    Change and Percent Change from Baseline in Mean Diurnal IOP at each post baseline visit except week 4.

  3. Change and Percent Change from baseline in Intraocular Pressure (IOP)

    Time frame: Assessment time point at each post baseline visit.

    Change and Percent Change from baseline in IOP at each IOP assessment time point at each post baseline visit.

  4. Percentage of Responders

    Time frame: Each Post Baseline Visit.

    Percentage of Responders (percent reduction from baseline in Mean Diurnal IOP: ≥20%, ≥25%, ≥30%) at each post baseline visit.

Sponsors and collaborators

Lead sponsor

Santen Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Phase III Study Including a Single-Arm, Open-Label, Multi-Dose PK Study Cohort and a Randomized, Evaluator-Masked, Active Drug Controlled, Parallel Group, Multicenter, Bridging Study Cohort With a Long-term Follow-up Phase Assessing the Efficacy and Safety of DE-117B Eye Drops in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 31, 2024
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.